Alector, Inc. (ALEC) vs Altimmune, Inc. (ALT)

Alector, Inc. and Altimmune, Inc. are both Biotechnology companies. Alector, Inc. and Altimmune, Inc. are of similar size ($391.6M and $375.4M). Altimmune, Inc. has negative trailing earnings, so its P/E is not meaningful; Alector, Inc. trades at 7.0×. Alector, Inc. grew revenue faster over the last twelve months: 151.2% against 130.0%. Alector, Inc. has the higher net margin (23.9% vs 0.00%) and the higher return on invested capital (0.00% vs −34.3%). Across the 17 metrics below, Alector, Inc. leads on 12 and Altimmune, Inc. on 5.

Valuation

Metric ALEC ALT Biotechnology median
P/E 6.98 n/m 11.19
P/S 1.59 6,571.16 9.15
P/B 2.37 0.64 2.23
Price to free cash flow n/m n/m 26.14
EV/EBITDA 3.80 n/m 0.71
EV/Sales 0.90 236.22 8.65
Earnings yield 14.33% (47.85%) (33.82%)
Free cash flow yield (54.19%) (25.39%) (23.58%)

Profitability

Metric ALEC ALT Biotechnology median
Gross margin 100.00% 100.00% 68.27%
Operating margin 20.16% 0.00% 0.00%
Net margin 23.87% 0.00% 0.00%
Free cash flow margin (86.31%) 0.00% 0.00%
Return on equity 47.52% (28.87%) (50.82%)
Return on assets 16.53% (25.58%) (46.08%)
Return on invested capital 0.00% (34.30%) 0.00%

Growth

Metric ALEC ALT Biotechnology median
Revenue growth (TTM) 151.23% 130.00% 7.42%
EPS growth (last fiscal year) (13.01%) 25.37% 29.86%
Revenue growth, 5-year CAGR (0.05%) (65.33%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALEC ALT Biotechnology median
Debt to equity 0.00 0.07 0.00
Current ratio 4.10 26.78 4.72
Net debt to EBITDA 1.61 2.49 1.01

Dividend

Metric ALEC ALT Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ALEC ALT Biotechnology median
Market cap 391.55m 375.41m 176.65m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack